News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
ChartMill Capital return
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Johnson & Johnson has acquired a significant new position in Xencor, Inc., purchasing 748,062 shares valued at approximately $12 billion, making Xencor its eighth-largest portfolio holding. Other institutional investors like BVF Inc. IL, Legal & General Group Plc, State Street Corp, Jefferies Financial Group …
Johnson & Johnson (J&J) recently invested $9.12 billion in Fate Therapeutics (FATE), acquiring over 3.3 million shares, which represents about 2.9% of the company. Despite an apparent inconsistency in the reported valuation relative to FATE's market cap, the biopharmaceutical company's shares rose, and it …
Johnson & Johnson has seen a 28% year-to-date return in 2026, outperforming market benchmarks. Despite strong Q2 results and upgraded guidance driven by pharmaceutical growth, the stock is now trading at a premium valuation. Analysts recommend a "hold" rating due to potential MedTech softness, …
Johnson & Johnson (JNJ) has seen a strong 28% total return year-to-date in 2026, outperforming broader market indices. Despite solid Q2 results and raised guidance, the stock's current valuation, trading at a premium, suggests it is fully priced. The article reiterates a hold rating, …
Rydar Equities Inc. significantly increased its stake in Johnson & Johnson (JNJ) during the second quarter, now holding 13,242 shares valued at approximately $3.36 million. This move is part of broader institutional interest, with 69.55% of JNJ stock owned by institutional investors and hedge …
Wedge Capital Management L L P NC significantly reduced its stake in Johnson & Johnson (JNJ) by selling 124,278 shares, representing a 96.7% decrease in its holdings. Despite this, Johnson & Johnson surpassed Q2 earnings and revenue estimates and announced a quarterly dividend of …
Envestnet Portfolio Solutions Inc. reduced its stake in Johnson & Johnson by 8.9% in Q2 2026, selling 6,962 shares but retaining 71,666 shares valued at $18.2 million. Johnson & Johnson exceeded quarterly earnings and revenue expectations, reporting $2.90 EPS and $25.31 billion in revenue, …
A Johnson & Johnson (JNJ.US) officer sold common stock totaling US$32.2 million. This transaction involved 200,000 shares at an average price of US$161.27. The article provides details of the insider sale and the officer's remaining holdings.
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson has delivered a 68.9% total return over the past 5 years, …
It has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 4.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to …
Sharemaestro market context Trend signal active 52 weeks +71.9% · Next-week setup positive 58.3%The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from …
Johnson & Johnson (JNJ) recently announced a leadership change in its Innovative Medicine sector with Jennifer Taubert's retirement and Tom Cavanaugh stepping in. This shift, combined with the FDA Priority Review for subcutaneous amivantamab in head and neck cancer, is expected to influence J&J's …
If you're not aware of them, there's a group of stocks known as Dividend Kings. This select group of companies have all increased their dividends annually for at least 50 consecutive years. A few of these Dividend Kings have done much better. Drug and …
Johnson & Johnson insider Joaquin Duato has filed to sell 123,291 shares of common stock through Fidelity Brokerage Services on August 13, 2026. These shares were acquired via stock option exercise for cash. This planned sale follows a previous sale of 48,480 shares on …
The article compares Johnson & Johnson (J&J) and AbbVie as investment options, focusing on their dividend characteristics and business strategies. J&J offers a safer, more diversified dividend with a 64-year streak and an AAA-rated balance sheet, while AbbVie provides a higher yield but carries …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …
Annex Advisory Services LLC decreased its stake in Johnson & Johnson by 16%, selling 5,431 shares and retaining 28,619 shares valued at $7.27 million. This comes as Johnson & Johnson reported strong second-quarter results with revenue up 6.6% to $25.31 billion and adjusted EPS …
Diversified Management Inc. significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) by 61.1% in the second quarter, selling 12,147 shares and leaving its holdings valued at $1.96 million. This comes as Johnson & Johnson reported stronger-than-expected Q2 earnings and raised its full-year outlook, …
Search by ticker symbol or company name and select a result to open its chart.